We are delighted to announce that our portfolio has blown past half a billion dollars raised to now collectively reach over $550M!
Just the last 12 months have seen many highlights – and this despite the very difficult market environments. Besides Alentis‘ recent $105M series C co-led by Jeito Capital, Novo Holdings and RA Capital Management , Engimmune Therapeutics raised $16.7M in seed financing co-led by Pureos Bioventures and Novo Holdings, and Cimeio Therapeutics closed a $50M series A financing from Versant Ventures last year.
“Since funding the first companies in 2018, our aim with BaseLaunch has been to find great innovation and derisk it by collaborating with exceptional founders to help them build successful companies that attract top-tier investors, partners and management teams,” Stephan Emmerth, Director of BaseLaunch explains. “Our portfolio has now raised over half a billion dollars in a very short time, with several companies conducting clinical studies for the ultimate goal of improving patient outcomes. This success has surpassed our wildest dreams! We are humbled and excited about this fantastic outcome and can hardly wait for the next five years of innovation and growth.”
Congratulations to each and every one of our portfolio companies for achieving such amazing milestones! We wish them all the very best for their next steps and an excellent future. Have a look at our portfolio companies over here:
In the meantime, our call for applications is open until 24 April 2023. Are you working on a breakthrough innovation in therapeutic products or platform projects? Are you inspired by the dedication and milestones of our portfolio companies? Then learn more and apply over here:
